摘要
目的 :检测胰腺癌患者血浆中微RNA(micro RNA,miRNA)的表达情况,并探讨其临床意义。方法 :收集43例胰腺癌患者(病例组)和21例正常健康人群(对照组)的血浆标本,采用实时荧光定量PCR法检测血浆样本中miRNA-21、miRNA-155和miRNA-483-3p的表达水平,并比较2组miRNA表达水平的差异及与临床病理特征之间的相关性。结果:病例组中miRNA-21、miRNA-483-3p和miRNA-155的表达水平分别为627.69±125.66、18.93±10.82和20.76±11.87,高于对照组的379.39±149.21、6.43±7.28和7.47±6.92,差异均具有统计学意义(P值均<0.001)。miRNA-21表达水平与肿瘤分期(P=0.001)以及是否发生肝脏转移(P<0.001)具有相关性。miRNA-21、miRNA-155、miRNA-483-3p和糖类抗原19-9(carbohydrate antigen 19-9,CA19-9)的受试者工作特征(receiver operating characteristic,ROC)曲线下面积分别为0.834、0.837、0.843和0.828,敏感度分别为88.4%、97.7%、83.7%和86.0%,特异度分别为85.7%、61.9%、71.4%和62.1%。在未行手术切除组29例患者中,miR NA21高表达组患者的中位总生存期为3.4个月,明显短于低表达组的15.4个月(P=0.001),而miR NA-155和miR NA-483-3p高表达组与低表达组患者的中位生存时间无明显差异,分别为4.5个月和7.3个月以及6.2个月和5.1个月。结论 :miRNA也许能成为胰腺癌的一种新的、无创的诊断标志物,并可能预测胰腺癌患者的预后。
Objective： To examine the levels of plasma microRNAs （miRNAs） in patients with pancreatic cancer, and to explore its clinical significance.Methods： The plasma samples from 43 patients with pancreatic cancer （study group） and 21 healthy volunteers （control group） were collected. Plasma miRNA-21, miRNA-155and miRNA-483-3p levels were detected using real-time fluorogenic quantitative PCR, and the correlation between miRNA levels and clinical features was evaluated.Results： The relative expression levels of plasma miRNA-21, miRNA-483-3p and miRNA-155 of patients with pancreatic cancer were 627.69±125.66, 18.93±10.82 and 20.76_＋11.87, respectively, which were higher than those of the healthy volunteers （379.39±149.21, 6.43± 7.28 and 7.47±6.92, respectively; all P 〈 0.001）. The plasma miRNA-21 level was associated with clinical stage of pancreatic cancer （P = 0.001） and liver metastasis （P 〈 0.001）. The areas under receiver operating characteristic （ROC） curves of miRNA-21, miRNA-155, miRNA- 483-3p and carbohydrate antigen 19-9 （CA19-9） were 0.834, 0.837, 0.843 and 0.828, respectively, with the sensitivities of 88.4%, 97.7%, 83.7% and 86.0%, respectively and the specificities of 85.7%, 61.9%, 71.4% and 62.1%, respectively. Moreover, in 29 pancreatic cancer patients not receiving suigical operation, the median survival time of patients with high-expression of miRNA-21 was significantly shorterned as compared with that of the patients with low-expression of miRNA-21 （3.4 vs 15.4 months, P = 0.001）. The median survival time of patients with high- and low-expressions of miRNA-155 was not significanly different （4.5 vs 6.2 months, P 〉 0.05）, which was also not significanly different between the high- and low-expressions of miRNA-483-3p （7.3 vs 5.1 , P 〉 0.05）.Conclusion： miRNAs may become a new biomarker in diagnosis of pancreatic cancer, and it also may be used to predict the prognosis.
出处
《肿瘤》
CAS
CSCD
北大核心
2015年第8期905-910,共6页
Tumor
关键词
胰腺肿瘤
微RNAS
血清学试验
预后
Pancreatic neoplasms
MicroRNAs
Serologic tests
Prognosis
